<DOC>
	<DOCNO>NCT00128440</DOCNO>
	<brief_summary>The primary objective study compare efficacy safety 200 μg 400 μg BEA 2180 BR tiotropium 5 μg placebo deliver Respimat® Inhaler daily four week patient COPD .</brief_summary>
	<brief_title>High Dose Trial COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>1 . Patients must relatively stable , moderate severe airway obstruction FEV1 &gt; =30 % &lt; = 60 % predict normal FEV1 &lt; =70 % FVC baseline PFTs Visit 1 ( timepoints ) . 2 . All patient must increase FEV1 least 12 % baseline ( th e 10 minute measurement ) 45 min inhalation 80 ? g Atrovent MDI . 3 . Male female patient 40 year age old . 4 . Smoker exsmoker history 10 pack year . 1 . Patients significant disease exclude . 2 . Patients history asthma allergic rhinitis exclude .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>84 Years</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>